Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Evaxion Biotech ( (EVAX) ) is now available.
On July 1, 2025, Evaxion A/S announced significant executive management changes to enhance its AI-Immunology platform’s value. Christian Kanstrup resigned as CEO, with Dr. Birgitte Rønø stepping in as interim CEO, and Thomas Schmidt was appointed as the permanent CFO. These changes aim to drive the company’s growth and strategic partnerships, positioning Evaxion for future advancements in its AI-driven vaccine development.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s strong R&D progress and strategic partnerships are its primary strengths. However, persistent financial instability, characterized by ongoing losses and reliance on debt, poses significant risks. Bullish technical indicators suggest potential short-term momentum, but valuation remains a concern with a negative P/E ratio.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, specializing in the development of AI-Immunology powered vaccines. The company utilizes its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections, aiming to transform patient care with innovative treatment options.
Average Trading Volume: 101,446
Technical Sentiment Signal: Sell
Current Market Cap: $3.48M
For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.